Mounjaro and Zepbound contain the same active ingredient, tirzepatide, are made by Eli Lilly and Company, and come in the same forms and strengths.[1][2] The labels differ in what each is indicated for, in how the dose steps are written, and in the maximum for children.

This page compares the two prescribing information documents, read on DailyMed on 20 November 2026. It does not compare results or side effects and does not say which is better. The prescriber decides which product and which dose.

Side by side

MounjaroZepbound
MakerEli Lilly and CompanyEli Lilly and Company
Active ingredientTirzepatideTirzepatide
Indication (in brief)Blood sugar control in type 2 diabetes (adults and children 10 and older); lowering the risk of major cardiovascular events in some adults with type 2 diabetesLong-term weight reduction in defined adult groups; moderate to severe obstructive sleep apnea in adults with obesity
FormsSingle-dose pen, single-dose vial, multi-dose vial (4 doses), KwikPen (4 doses)The same four
Strengths per dose2.5, 5, 7.5, 10, 12.5, 15 mgThe same six
How oftenOnce weekly, any time of day, with or without mealsOnce weekly, any time of day, with or without meals
First step on the label2.5 mg once weekly2.5 mg once weekly for 4 weeks
Maximum15 mg once weekly (adults); 10 mg once weekly (children 10 and older)15 mg once weekly
Missed doseWithin 4 days (96 hours), otherwise skipWithin 4 days (96 hours), otherwise skip
Changing the weekly dayAt least 3 days (72 hours) between dosesAt least 3 days (72 hours) between doses
Half-life in section 12.3Approximately 5 daysApproximately 5–6 days

Sources: sections 1, 2, 3 and 12.3 of each label.[1][2] The indication lines are our short, neutral paraphrase of section 1.

Dose steps on each label

Mounjaro. “The recommended starting dosage of MOUNJARO is 2.5 mg injected subcutaneously once weekly.” If more glycemic control is needed, the dose goes up in 2.5 mg steps after at least 4 weeks on the current dose, to a maximum of 15 mg once weekly for adults and 10 mg once weekly for children.[1]

Zepbound. The label starts at 2.5 mg once weekly for 4 weeks and says “The 2.5 mg dosage is for treatment initiation and is not approved as a maintenance dosage.” After 4 weeks it goes to 5 mg, and may then go up in 2.5 mg steps after at least 4 weeks on the current dose. Maintenance is 5 mg, 10 mg or 15 mg once weekly for weight reduction, and 10 mg or 15 mg for obstructive sleep apnea. The maximum is 15 mg once weekly.[2]

These are what each label lists, not a plan. The prescriber sets the dose.

Same forms, same volumes

Both labels list each form in the same six strengths:[1][2]

  • Single-dose pen or vial: 2.5 to 15 mg in 0.5 mL. One dose each.
  • Multi-dose vial: 10 to 60 mg in 2.4 mL (4.17 to 25 mg/mL). Four doses of 0.6 mL.
  • KwikPen: 10 to 60 mg in 2.4 mL. Four fixed doses.

Both labels also give the same example syringe for vials: “a 1 mL syringe capable of measuring a 0.5 mL or 0.6 mL dose”. One difference: the Mounjaro label says its KwikPen “is not recommended for self-administration by pediatric patients”, and both say it is not recommended for self-administration by those who are visually impaired.

The volume arithmetic is on Zepbound and Mounjaro vials: mL per dose, and the forms are compared on Zepbound vial vs pen vs KwikPen.

Missed doses

The two labels use the same words: “administer [the product] as soon as possible within 4 days (96 hours) after the missed dose. If more than 4 days have passed, skip the missed dose and administer the next dose on the regularly scheduled day.”[1][2]

Storage

Section 16.2 is the same on both labels: single-dose pens and vials can, if needed, be unrefrigerated at up to 30 °C for up to a total of 21 days; multi-dose vials and KwikPens have 30-day and 4-dose limits.[1][2] The full wording is on how long Zepbound or Mounjaro can be unrefrigerated.

Using them together

The Zepbound label’s limitations of use say: “ZEPBOUND contains tirzepatide. Coadministration with other tirzepatide-containing products or with any glucagon-like peptide-1 (GLP-1) receptor agonist is not recommended.”[2]

For a vial, the dose volume calculator in label-concentration mode turns the label’s mg per mL into mL and units. See also the Mounjaro and Zepbound label pages, the tirzepatide calculator and tirzepatide half-life.

Last checked against the labels: 20 November 2026.

Mounjaro, Zepbound and KwikPen are registered trademarks of Eli Lilly and Company. Kept is independent and not affiliated with, endorsed by or sponsored by Eli Lilly and Company.